pSivida Limited (PSDV) Says RetisertTM Drug Implant Receives Product Specific Bill Code and Medicare Reimbursement Rate
pSivida Limited (NASDAQ: PSDV) announced that Retisert, developed jointly by pSivida and Bausch & Lomb (NYSE: BOL), has been allocated a product specific J-Code by the Centers for Medicare and Medicaid Services (CMS) in the United States.
The RetisertTM implant was approved as a single indication orphan drug by the United States Food and Drug Administration for the treatment of chronic noninfectious posterior segment uveitis, a sight threatening inflammatory disease and a major cause of blindness. RetisertTM is surgically placed into the back of the eye and releases the steroid, fluocinolone acetonide at a constant rate over a period of up to 30 months. Marketed in the United States by Bausch & Lomb, pSivida receives royalties on sales.
The RetisertTM implant was approved as a single indication orphan drug by the United States Food and Drug Administration for the treatment of chronic noninfectious posterior segment uveitis, a sight threatening inflammatory disease and a major cause of blindness. RetisertTM is surgically placed into the back of the eye and releases the steroid, fluocinolone acetonide at a constant rate over a period of up to 30 months. Marketed in the United States by Bausch & Lomb, pSivida receives royalties on sales.
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
